Fate Therapeutics, Inc. (FATE): Price and Financial Metrics
FATE Price/Volume Stats
| Current price | $3.45 | 52-week high | $8.83 |
| Prev. close | $3.39 | 52-week low | $1.63 |
| Day low | $3.35 | Volume | 832,400 |
| Day high | $3.52 | Avg. volume | 2,427,978 |
| 50-day MA | $3.92 | Dividend yield | N/A |
| 200-day MA | $4.61 | Market Cap | 392.72M |
FATE Stock Price Chart Interactive Chart >
Fate Therapeutics, Inc. (FATE) Company Bio
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular immunotherapies for cancer and immune disorders in the United States. The company was founded in 2007 and is based in San Diego, California.
Latest FATE News From Around the Web
Below are the latest news stories about FATE THERAPEUTICS INC that investors may wish to consider to help them evaluate FATE as an investment opportunity.
Fate Therapeutics (FATE) Upgraded to Buy: Here's WhyFate Therapeutics (FATE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
12 Most Promising Cancer Stocks According to AnalystsIn this piece, we will take a look at the 12 most promising cancer stocks according to analysts. If you want to skip our overview of the latest trends in the cancer treatment sector, then you can take a look at the 5 Most Promising Cancer Stocks According to Analysts. The advent of technology and […] |
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 350,000 shares of the Company’s common stock at an exercise price per share of $ |
Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue?Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call TranscriptFate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Welcome to the Fate Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are mode. The call is being webcast live on the Investors section of Fate’s website at fatetherapeutics.com. As a reminder, today’s call is being recorded. […] |
FATE Price Returns
| 1-mo | 2.37% |
| 3-mo | -8.49% |
| 6-mo | -52.28% |
| 1-year | 41.39% |
| 3-year | -94.96% |
| 5-year | -80.23% |
| YTD | -7.75% |
| 2023 | -62.93% |
| 2022 | -82.76% |
| 2021 | -35.65% |
| 2020 | 364.64% |
| 2019 | 52.53% |
Continue Researching FATE
Here are a few links from around the web to help you further your research on Fate Therapeutics Inc's stock as an investment opportunity:Fate Therapeutics Inc (FATE) Stock Price | Nasdaq
Fate Therapeutics Inc (FATE) Stock Quote, History and News - Yahoo Finance
Fate Therapeutics Inc (FATE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...